Amphotericin B

Amphotericin B

Clinical data
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	slow i.v.-infusion only
ATC code	A01AB04 (WHO) A07AA07 (WHO), G01AA03 (WHO), J02AA01 (WHO)
Legal status
Legal status	Rx-only, hospitalization recommended.
Pharmacokinetic data
Bioavailability	100% (IV)
Metabolism	renal
Elimination half-life	initial phase : 24 hours, second phase : approx. 15 days
Excretion	40% found in urine after single cumulated over several days biliar excretion also important
Identifiers
IUPAC name (1R-(1R*,3S*,5R*,6R*,9R*,11R*,15S*,16R*,17R*, 18S*,19E,21E,23E,25E,27E,29E,31E,33R*, 35S*,36R*,37S*))-33-((3-Amino-3,6-dideoxy-beta- D-mannopyranosyl)oxy)- 1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl -13-oxo-14,39-dioxabicyclo(33.3.1)nonatriaconta- 19,21,23,25,27,29,31-heptaene-36- carboxylic acid
CAS Number	1397-89-3
PubChem CID	14956
DrugBank	APRD00797
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C47H73NO17
Molar mass	924.084

WikiDoc Resources for Amphotericin B
Articles
Most recent articles on Amphotericin B Most cited articles on Amphotericin B Review articles on Amphotericin B Articles on Amphotericin B in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Amphotericin B Images of Amphotericin B Photos of Amphotericin B Podcasts & MP3s on Amphotericin B Videos on Amphotericin B
Evidence Based Medicine
Cochrane Collaboration on Amphotericin B Bandolier on Amphotericin B TRIP on Amphotericin B
Clinical Trials
Ongoing Trials on Amphotericin B at Clinical Trials.gov Trial results on Amphotericin B Clinical Trials on Amphotericin B at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Amphotericin B NICE Guidance on Amphotericin B NHS PRODIGY Guidance FDA on Amphotericin B CDC on Amphotericin B
Books
Books on Amphotericin B
News
Amphotericin B in the news Be alerted to news on Amphotericin B News trends on Amphotericin B
Commentary
Blogs on Amphotericin B
Definitions
Definitions of Amphotericin B
Patient Resources / Community
Patient resources on Amphotericin B Discussion groups on Amphotericin B Patient Handouts on Amphotericin B Directions to Hospitals Treating Amphotericin B Risk calculators and risk factors for Amphotericin B
Healthcare Provider Resources
Symptoms of Amphotericin B Causes & Risk Factors for Amphotericin B Diagnostic studies for Amphotericin B Treatment of Amphotericin B
Continuing Medical Education (CME)
CME Programs on Amphotericin B
International
Amphotericin B en Espanol Amphotericin B en Francais
Business
Amphotericin B in the Marketplace Patents on Amphotericin B
Experimental / Informatics
List of terms related to Amphotericin B

Overview

Amphotericin B (Fungilin, Fungizone, Abelcet, AmBisome, Fungisome, Amphocil, Amphotec) is a polyene antifungal drug, often used intravenously for systemic fungal infections. It was originally extracted from Streptomyces nodosus, a filamentous bacterium, in 1955 at the Squibb Institute for Medical Research from cultures of an undescribed streptomycete isolated from the soil collected in the Orinoco River region of Venezuela. Its name originates from the chemical's amphoteric properties. Two amphotericins, Amphotericin A and Amphotericin B are known, but only B is used clinically because it is significantly more active in vivo. Currently the drug is available as plain Amphotericin B, as cholesteryl sulfate complex, as lipid complex, and as liposomal formulation. The latter formulations have been developed to improve tolerability for the patient but may show considerably different pharmacokinetic characteristics compared to plain Amphotericin B.

Uses

Oral preparations of amphotericin B are used to treat oral thrush; these are virtually nontoxic. The main i.v. use is in systemic fungal infections (e.g. in immunocompromised patients), and in visceral leishmaniasis. Aspergillosis, cryptococcus infections (e.g. meningitis) and candidiasis are treated with amphotericin B. It is also used empirically in febrile immunocompromised patients who do not respond to broad-spectrum antibiotics.

Mechanism of action

As with other polyene antifungals, amphotericin B associates with ergosterol, a membrane chemical of fungi, forming a pore that leads to K⁺ leakage and fungal cell death. Recently, however, researchers found evidence that pore formation is not necessarily linked to cell death (i.e. Angewandte Chemie Int. Ed. Engl. 2004). The actual mechanism of action may be more complex and multi-faceted.

Amphotericin B is believed to interact with membrane sterols (ergosterol) to produce an aggregate that forms a transmembrane channel. Intermolecular hydrogen bonding interactions among hydroxyl, carboxyl and amino groups stabilize the channel in its open form, destroying activity and allowing the cytoplasmic contents to leak out.

Side effects

Very often a serious acute reaction after the infusion (1 to 3 hours later) is noted consisting of fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, dyspnea, and tachypnea. This reaction sometimes subsides with later applications of the drug and may in part be due to histamine liberation. An increase in prostaglandin-synthesis may also play a role. Often the most difficult decision has to be made, whether the fever is disease- or drug-related. In order to decrease the likelihood and severity of the symptoms, initial doses should be low and increased slowly. The liposomal preparation obviously has a lower incidence of the syndrome. Acetaminophen, pethidine, diphenhydramine and/or hydrocortisone have all been used to treat or prevent the syndrome, but the prophylactic use of these drugs should be limited.

Nephrotoxicity (kidney damage) is a major issue and can be severe and/or irreversible. It is much milder when amphotericin B is delivered in liposomes (AmBisome). Electrolyte imbalances (e.g. hypokalemia and hypocalcemia) may also occur.

Increased liver enzymes and hepatotoxicity up to acute liver failure, several forms of anemia and other blood dyscrasias (leukopenia, thrombopenia), serious cardiac arrhythmias (including ventricular fibrillation), and cardiac failure have also been reported frequently. Skin reactions, including serious forms, are also possible.

Interactions

• Flucytosine : Toxicity of Flucytosine increased and vice versa
• Diuretics or Cisplatin : Increased renal toxicity and incrised risk of hypokalemia
• Corticosterioids : Increased risk of hypokalemia
• Cytostatic drugs : Increased risk of kidney damage, hypotension and bronchospasms.
• Other nephrotoxic drugs : Increased risk of serious renal damage. Monitor patients closely.
• Foscarnet, Ganciclovir, Tenofovir, Adefovir : Risk of hematological and renal side-effects of Amphotericin B increased.
• Transfusion of Leukocytes : Risk of pulmonal (lung) damage. Space intervals between the application of Amphotericin B and the transfusion and monitor pulmonary function.

Liposomal and lipid complex preparations

From studies it appears that liposomal amphotericin B preparations exhibit fewer side-effects while having similar efficacy. Various preparations have recently been introduced. All of these are more expensive than plain Amphotericin B.

AmBisome is a liposomal formulation of amphotericin B for injection, developed by NeXstar Pharmaceuticals (acquired by Gilead Sciences in 1999). It is marketed by Gilead in Europe and licensed to Astellas Pharma (formerly Fujisawa Pharmaceuticals) for marketing in the USA, and Sumitomo Pharmaceuticals in Japan.

Fungisome is a liposomal complex of Amphotericin B and being the latest and cheapest addition to the lipid formulations of Amphotericin B has many advantages. It is marketed by Lifecare Innovations of India. Other formulations include Amphotec (Intermune) and Abelcet (Enzon Pharmaceuticals).

Abelcet is not a liposomal preparation but rather a lipid complex preparation.

External links

• Fungisome web site run by Lifecare Innovations
• AmBisome web site run by Astella Pharma
• "Special issue". Journal of Postgraduate Medicine. 51 (Suppl). 2005.